SAN FRANCISCO--(BUSINESS WIRE)--Vector Capital, a leading private equity firm specializing in transformational investments in established technology businesses, today announced its investment in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vector Capital (“Vector”), a leading private equity firm specializing in transformational investments in established technology businesses, today announced it has ...

Seasoned Life Science Industry Executive with More Than 30 Years of Experience in Cell and Gene Therapy, Including Senior Level Viral Vector Development Positions with Fujifilm Diosynth ...

The science of gene therapy is enjoying a renaissance after ups and downs over the past 25 years. The heart of this field still largely relies on viral vector gene transfer systems that have evolved ...

Pathway-selective gene delivery would be critical for future gene therapy against neuropsychiatric disorders, traumatic neuronal injuries, or neurodegenerative diseases, because the impaired functions ...

Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More The race to develop the best search engine technology heated up again ...

As gene and cell therapies mature, developers are increasingly looking beyond existing delivery systems to address challenges around targeting, immunogenicity, manufacturability, and cost. Dr. Angelo ...